A 42-year-old woman from Mumbai with a 5-year history of asthma and chronic rhinosinusitis presents with worsening nasal obstruction and anosmia. Nasal endoscopy reveals bilateral polypoid masses. She reports intolerance to aspirin and NSAIDs, with symptoms of urticaria and bronchospasm after exposure. CT paranasal sinuses shows bilateral ethmoid and maxillary sinus opacification with polypoid masses. What is the most appropriate first-line pharmacological management for her nasal polyposis?

Explanation

## First-Line Management of Nasal Polyposis: Intranasal Corticosteroids ### Clinical Context: Samter Triad **Key Point:** This patient has **Samter triad** (aspirin/NSAID intolerance + asthma + nasal polyposis), a specific phenotype of CRSwNP with eosinophilic inflammation. The presence of this triad does NOT change the first-line treatment approach. ### Treatment Hierarchy for CRSwNP ```mermaid flowchart TD A[Bilateral nasal polyps diagnosed]:::outcome --> B[Start intranasal corticosteroids]:::action B --> C{Response after 3-6 months?}:::decision C -->|Good| D[Continue indefinitely]:::action C -->|Partial| E[Add oral antihistamine or LTRA]:::action C -->|Poor| F[Consider oral corticosteroids]:::action F --> G{Response?}:::decision G -->|Yes| H[Taper and maintain on intranasal]:::action G -->|No| I[Functional Endoscopic Sinus Surgery]:::action I --> J[Post-op intranasal steroids + maintenance]:::action ``` ### Why Intranasal Corticosteroids Are First-Line | Aspect | Intranasal Steroids | Oral Steroids | LTRAs | Antihistamines | |--------|-------------------|---------------|-------|----------------| | **Efficacy in CRSwNP** | High (60–80% response) | High but systemic | Moderate (30–40%) | Low (10–20%) | | **Safety profile** | Excellent (minimal systemic absorption) | Poor (long-term side effects) | Good | Good | | **First-line role** | YES | No (reserved for failures) | Adjunctive | Adjunctive | | **Onset of action** | 2–4 weeks | 1–2 weeks | 4–6 weeks | Days | | **Long-term use** | Safe and recommended | Not recommended >3 weeks | Safe | Safe | **High-Yield:** Intranasal corticosteroids have negligible systemic absorption (<1% bioavailability) and are safe for long-term use, making them the ideal first-line agent. ### Mechanism of Action in Polyposis 1. **Reduces mucosal edema** via suppression of inflammatory mediators (IL-5, eotaxin) 2. **Decreases eosinophilic infiltration** in polyp tissue 3. **Inhibits mast cell degranulation** and histamine release 4. **Stabilizes epithelial barrier** function **Clinical Pearl:** In Samter triad patients, intranasal corticosteroids are still the foundation of therapy. LTRAs (e.g., montelukast) may provide additional benefit as an adjunct because they target leukotriene-mediated eosinophilic inflammation, but they are NOT monotherapy for polyps. ### Recommended Dosing **Key Point:** Use high-dose intranasal corticosteroids initially: - **Mometasone furoate:** 200 μg (2 sprays of 100 μg each) per nostril once daily - **Fluticasone propionate:** 200 μg (2 sprays) per nostril once daily - **Duration:** Minimum 3–6 months before assessing response ### Role of Oral Corticosteroids **Warning:** Oral corticosteroids are NOT first-line because: - Risk of systemic side effects (hyperglycemia, osteoporosis, immunosuppression) - Short duration of benefit (polyps often recur after tapering) - Reserved for severe cases failing intranasal therapy or pre-operative shrinkage ### Special Consideration: Samter Triad Management **Mnemonic:** **NSAID-ASA** = Avoid NSAIDs and aspirin - Patient must avoid all NSAIDs and aspirin due to cross-reactivity - Acetaminophen is safe - Selective COX-2 inhibitors (e.g., celecoxib) may be tolerated but require cautious introduction - Aspirin desensitization is an option in specialized centers but not routine first-line **Clinical Pearl:** Addition of a leukotriene receptor antagonist (montelukast 10 mg daily) is reasonable as adjunctive therapy in Samter triad patients because leukotrienes drive eosinophilic inflammation, but it should NOT replace intranasal corticosteroids. [cite:Scott-Brown's Otorhinolaryngology 8e Ch 34; Harrison 21e Ch 409]